Gold and Silver Hit New Highs; NVIDIA's GB300 Shipments Expected to Reach 55,000 Units Next Year

Stock News07:59

**Key Highlights** China's Ministry of Finance and other departments issued guidelines to clarify the definition of domestically produced goods under government procurement policies. Products manufactured in bonded zones or special customs areas qualify as domestically produced, while medical devices must obtain regulatory approval.

**Market Overview** Global gold and silver prices surged to record highs. COMEX gold futures rose 2.13% to $4,480.6/oz, while silver futures climbed 2.37% to $69.09/oz. U.S. stocks posted gains, with the Dow Jones up 0.47%, the S&P 500 up 0.64%, and the Nasdaq up 0.52%. Tech stocks were mixed, with Micron Technology hitting an all-time high (+4%), while NVIDIA and Tesla rose over 1%. Commercial space stocks rallied, with Rocket Lab surging 10% for a three-day cumulative gain of 44%.

**Sector Focus** - **Pharma & E-Commerce**: New regulations for online drug and medical device information services took effect, impacting Hong Kong-listed healthcare platforms. - **Commodities**: Hong Kong’s Financial Secretary Chen Maobo highlighted the city’s potential in global commodity markets, citing China’s role as a major consumer. A gold central clearing system is set for trial in 2026, with storage capacity expanding to 1,000 metric tons. - **Tech**: NVIDIA’s GB300 AI server shipments are projected to grow 129% YoY to 55,000 units in 2026, driven by demand from Microsoft and Meta. The next-gen Vera Rubin 200 platform is slated for Q4 2026 release, benefiting suppliers like Foxconn and Quanta.

**Corporate Updates** - **CTG DUTY-FREE (01880)**: Sales surged 61% YoY on the first day of Hainan’s duty-free island policy, with 1.61 billion yuan ($225M) in purchases. - **NuoBiKan (02635)**: Shares soared 275% in gray-market trading ahead of its Hong Kong debut. - **Others**: CGN Power (01816) adjusted operational timelines for its Huizhou nuclear units, while Sihuan Pharma (02256) secured NMPA approval for its CSF-1R inhibitor.

**Earnings Spotlight** Sanhua Intelligent Controls (02050) forecasted a 25–50% rise in 2025 net profit, citing strong operational performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment